Author:
Newton Benjamin,Chiang Anne C.
Publisher
Springer International Publishing
Reference77 articles.
1. Govindan R, Page N, Morgensztern D et al (2006) Changing epidemiology of small cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic and end results database. J Clin Oncol 24(28):4349–4544
2. Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP (2019) Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer 19(5):289–297
3. Gay CM, Stewart CA, Park EM et al (2021) Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39(3): 346–360
4. Tian Y, Zhai X, Han A, Zhu H, Yu J (2019) Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. J Hematol Oncol 12(67):1–12
5. Murray N, Coy P, Pater JL (1993) Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11(2):336–344